<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Atea Pharmaceuticals, Inc. — News on 6ix</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc</link>
<description>Latest news and press releases for Atea Pharmaceuticals, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 13 May 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/atea-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683549f978dffbe2df0e47ab.webp</url>
<title>Atea Pharmaceuticals, Inc.</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc</link>
</image>
<item>
<title>Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-to-present-three-abstracts-at-easl-2026-congress-highlighting-progress-across-viral-hepatitis-pipeline</link>
<guid isPermaLink="true">https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-to-present-three-abstracts-at-easl-2026-congress-highlighting-progress-across-viral-hepatitis-pipeline</guid>
<pubDate>Wed, 13 May 2026 11:00:00 GMT</pubDate>
<description>BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that three abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27-30th in Barcelona, Spain. The presentations include two posters supporting Atea’</description>
</item>
<item>
<title>Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-to-host-first-quarter-2026-financial-results-and-business-update-conference-call-on-may-12-2026</link>
<guid isPermaLink="true">https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-to-host-first-quarter-2026-financial-results-and-business-update-conference-call-on-may-12-2026</guid>
<pubDate>Tue, 05 May 2026 11:00:00 GMT</pubDate>
<description>BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Tuesday, May 12, 2026, at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2026, and to provide a business update. To access the live conferen</description>
</item>
<item>
<title>Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-64</link>
<guid isPermaLink="true">https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-64</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and</description>
</item>
<item>
<title>Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-to-host-fourth-quarter-and-full-year-2025-financial-results-and-business-update-conference-call-on-march-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-to-host-fourth-quarter-and-full-year-2025-financial-results-and-business-update-conference-call-on-march-5-2026</guid>
<pubDate>Thu, 26 Feb 2026 12:00:00 GMT</pubDate>
<description>BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 5, 2026, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2025, and to provide a business update. To acc</description>
</item>
<item>
<title>Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-presents-preclinical-results-supporting-first-in-class-potential-of-at-587-for-treatment-of-hepatitis-e-virus-at-croi-2026</link>
<guid isPermaLink="true">https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-presents-preclinical-results-supporting-first-in-class-potential-of-at-587-for-treatment-of-hepatitis-e-virus-at-croi-2026</guid>
<pubDate>Tue, 24 Feb 2026 12:00:00 GMT</pubDate>
<description>Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced in vitro results showing that two proprietary oral nucleotide analogs, AT-587 and AT-2490,</description>
</item>
<item>
<title>Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-highlight-2026-strategic-120000087</link>
<guid isPermaLink="true">https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-highlight-2026-strategic-120000087</guid>
<pubDate>Thu, 08 Jan 2026 12:00:00 GMT</pubDate>
<description>Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD Trial Outside North America Expected Year-End 2026 C-BEYOND and C-FORWARD Are the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for Treatment of HCV Initiation of HEV Phase 1 Clinical Program for Product Candidate AT-587 Anticipated Mid-2026 BOSTON, Jan. 08, 2026 (GLOBE NEWSWI</description>
</item>
<item>
<title>Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-present-44th-annual-120000233</link>
<guid isPermaLink="true">https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-present-44th-annual-120000233</guid>
<pubDate>Tue, 06 Jan 2026 12:00:00 GMT</pubDate>
<description>BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in ...</description>
</item>
<item>
<title>Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-completes-patient-enrollment-120000537</link>
<guid isPermaLink="true">https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-completes-patient-enrollment-120000537</guid>
<pubDate>Mon, 22 Dec 2025 12:00:00 GMT</pubDate>
<description>Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside North America, Enrollment Completion Expected Mid-2026 with Topline Results Anticipated Year-End 2026 C-BEYOND AND C-FORWARD are the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for Treatment of HCV BOSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: A</description>
</item>
<item>
<title>Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-present-8th-annual-120000906</link>
<guid isPermaLink="true">https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-present-8th-annual-120000906</guid>
<pubDate>Wed, 19 Nov 2025 12:00:00 GMT</pubDate>
<description>BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, Dec</description>
</item>
<item>
<title>Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-reports-third-quarter-210500446</link>
<guid isPermaLink="true">https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-reports-third-quarter-210500446</guid>
<pubDate>Wed, 12 Nov 2025 21:05:00 GMT</pubDate>
<description>Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North America Trial Expected Mid-2026 New Data Show Bemnifosbuvir Has Unique Dual Mechanism Against HCV New Data Presented at The Liver Meeting®, the Annual Meeting of AASLD, Support Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Therapy for the Treatment of HCV Company Announces New Hepatitis E Virus (HEV) Development Program Company Holding Conference Call Today at 4:30 PM</description>
</item>
<item>
<title>Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-presents-data-supporting-130000487</link>
<guid isPermaLink="true">https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-presents-data-supporting-130000487</guid>
<pubDate>Fri, 07 Nov 2025 13:00:00 GMT</pubDate>
<description>Company Hosting Virtual KOL Panel Event Thursday, November 13th at 10:00 AM ETBOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the presentation of new modeling data predicting that the Company’s combination regimen of bemnifosbuvir (BEM), a nucleotide analog polymerase inhibitor, and ru</description>
</item>
<item>
<title>Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-host-third-quarter-120000560</link>
<guid isPermaLink="true">https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-host-third-quarter-120000560</guid>
<pubDate>Wed, 05 Nov 2025 12:00:00 GMT</pubDate>
<description>BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, November 12, 2025, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2025, and to provide a business update. To access the live c</description>
</item>
<item>
<title>Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-host-virtual-hcv-110000403</link>
<guid isPermaLink="true">https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-host-virtual-hcv-110000403</guid>
<pubDate>Wed, 22 Oct 2025 11:00:00 GMT</pubDate>
<description>BOSTON, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a virtual key opinion leader (KOL) event on Thursday, November 13, 2025 at 10:00 AM ET to discuss a wide range of hepatitis C virus (HCV)-related topics including the current HCV patient population, the importance of ear</description>
</item>
<item>
<title>Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-present-data-supporting-120000574</link>
<guid isPermaLink="true">https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-present-data-supporting-120000574</guid>
<pubDate>Tue, 07 Oct 2025 12:00:00 GMT</pubDate>
<description>BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that new data will be presented supporting the combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor and ruzasvir, an NS5A inhibitor, as a potential best-in-class regimen for the treatment of hepatitis C (HCV) inf</description>
</item>
<item>
<title>Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-present-morgan-stanley-110000653</link>
<guid isPermaLink="true">https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-present-morgan-stanley-110000653</guid>
<pubDate>Tue, 02 Sep 2025 11:00:00 GMT</pubDate>
<description>BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 1:05 p.m. ET in New York, NY. A live webcast of the presentation</description>
</item>
<item>
<title>Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-reports-second-quarter-200500677</link>
<guid isPermaLink="true">https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-reports-second-quarter-200500677</guid>
<pubDate>Thu, 07 Aug 2025 20:05:00 GMT</pubDate>
<description>Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV Four Scientific Posters Presented at EASL, Including Final Results from Phase 2 Study of Bemnifosbuvir/Ruzasvir Regimen Confirming 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration Regimen of Bemnifosbuvir/Ruzasvir has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect BOSTON, Aug. 07</description>
</item>
<item>
<title>Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-host-second-quarter-110000638</link>
<guid isPermaLink="true">https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-host-second-quarter-110000638</guid>
<pubDate>Thu, 31 Jul 2025 11:00:00 GMT</pubDate>
<description>BOSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, August 7, 2025, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2025, and to provide a business update. To access the live conferenc</description>
</item>
<item>
<title>Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-announces-continued-advancement-110000777</link>
<guid isPermaLink="true">https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-announces-continued-advancement-110000777</guid>
<pubDate>Tue, 24 Jun 2025 11:00:00 GMT</pubDate>
<description>C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect HCV Infection Remains a Significant Global Health Burden, with Approximately 50 Million People Infected, Including up to 4 Million in US BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Atea Phar</description>
</item>
<item>
<title>Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-reports-first-quarter-201100224</link>
<guid isPermaLink="true">https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-reports-first-quarter-201100224</guid>
<pubDate>Mon, 12 May 2025 20:11:00 GMT</pubDate>
<description>Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting Potential Best-in-Class Profile Presented at European Association for the Study of the Liver (EASL) Congress 2025 Virtual Investor Event with Key Opinion Leader Insights on HCV to be Held May 14, 2025, at 10:00 AM ET BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (A</description>
</item>
<item>
<title>Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025</title>
<link>https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-announces-full-results-110000208</link>
<guid isPermaLink="true">https://6ix.com/company/atea-pharmaceuticals-inc/news/atea-pharmaceuticals-announces-full-results-110000208</guid>
<pubDate>Wed, 07 May 2025 11:00:00 GMT</pubDate>
<description>Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study Showed Low Risk for Drug-Drug Interactions with Regimen When Co-Administered with Standard HIV Treatment Regimen Bemnifosbuvir Was Generally Safe and Well Tolerated with No Dose Adjustment Neededin Phase 1 Studies in Participants with Hepatic or Renal Impairment Atea Pharmaceuticals to Host Virtual HCV KOL Panel</description>
</item>
</channel>
</rss>